A Paudel



  1. Zellnitz S, Pinto J, Brunsteiner M, Schroettner H, Khinast J, Paudel A. Tribo-Charging Behaviour of Inhalable Mannitol Blends with Salbutamol Sulphate. Pharm Res. 2019;36:80 pubmed publisher
    ..For their binary blends, the amount and nature of fines seem to govern inter-particle contacts critically impacting charge evolution. ..
  2. Hörmann T, Jager N, Funke A, Mürb R, Khinast J, Paudel A. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization. Int J Pharm. 2018;553:408-421 pubmed publisher
    ..Finally, a feasible formulation window within a polymer ratio of 1:2-2:3 Eudragit E:HPMC was identified in which Eudragit E acts as a dissolution rate enhancer and ASD stabilizer during dissolution. ..
  3. Faulhammer E, Wahl V, Zellnitz S, Khinast J, Paudel A. Carrier-based dry powder inhalation: Impact of carrier modification on capsule filling processability and in vitro aerodynamic performance. Int J Pharm. 2015;491:231-42 pubmed publisher
    ..8%) and the in vitro aerodynamic performance (FPF of 12%). ..
  4. Faulhammer E, Kovalcik A, Wahl V, Markl D, Stelzer F, Lawrence S, et al. Multi-methodological investigation of the variability of the microstructure of HPMC hard capsules. Int J Pharm. 2016;511:840-54 pubmed publisher
  5. Scarpa M, Stegemann S, Hsiao W, Pichler H, Gaisford S, Bresciani M, et al. Orodispersible films: Towards drug delivery in special populations. Int J Pharm. 2017;523:327-335 pubmed publisher
    ..Overall, this article aims to stimulate further research to fill the current knowledge gap between manufacturing and administration requirements of ODF targeting specific patient subpopulations such as geriatrics. ..
  6. Pinto J, Radivojev S, Zellnitz S, Roblegg E, Paudel A. How does secondary processing affect the physicochemical properties of inhalable salbutamol sulphate particles? A temporal investigation. Int J Pharm. 2017;528:416-428 pubmed publisher
    ..g. relative standard deviation of drug content of 11.3, 7.0 and 21.6%, respectively). ..
  7. Faulhammer E, Zellnitz S, Wutscher T, Stranzinger S, Zimmer A, Paudel A. Performance indicators for carrier-based DPIs: Carrier surface properties for capsule filling and API properties for in vitro aerosolisation. Int J Pharm. 2018;536:326-335 pubmed publisher